Related Experiment Videos
Exploiting the innate immune system to control allergic asthma.
1Inserm U547, Institut Pasteur de Lille, France. david.dombrowicz@pasteur-lille.fr
European Journal of Immunology
|October 7, 2005
Summary
Treatment with alpha-galactosylceramide, a Natural Killer T (NKT) cell ligand, surprisingly inhibits allergic asthma by increasing IFN-gamma, not IL-10, in mouse models.
Area of Science:
- Immunology: Investigating the complex interplay between innate and adaptive immunity.
- Allergy Research: Focusing on the mechanisms underlying allergic asthma and potential therapeutic interventions.
Background:
- Natural Killer T (NKT) cells bridge innate and acquired immunity, influencing immune responses through cytokine secretion.
- NKT cells have been implicated as crucial in the development of allergic asthma, a Th2-mediated condition.
Discussion:
- Paradoxical findings emerge from studies using alpha-galactosylceramide (a specific NKT ligand) in mouse models of allergic asthma.
- Treatment with this NKT ligand demonstrates significant inhibition of key asthma parameters, including airway hyperreactivity, eosinophilia, and IgE production.
Key Insights:
- The inhibitory effect is attributed to increased Interferon-gamma (IFN-gamma) synthesis.
- This contrasts with the expected role of Interleukin-10 (IL-10), suggesting a non-regulatory mechanism drives the therapeutic outcome.
Outlook:
- These findings challenge previous assumptions about NKT cell roles in allergic diseases.
- Further research into NKT cell modulation could reveal novel therapeutic strategies for allergic asthma.